Completed PHASE2 NCT00003234

Vinorelbine in Treating Children With Recurrent or Refractory Cancers

A Phase II Study of Navelbine (Vinorelbine) In Children With Recurrent Or Refractory Malignancies

Sponsor: Children's Oncology Group

Conditions Brain and Central Nervous System Tumors Neuroblastoma Sarcoma

Updated 6 times since 2017 Last updated: Jul 25, 2014 Started: May 31, 1998 Primary completion: Mar 31, 2006 Completion: Mar 31, 2007

This PHASE2 trial investigates Brain and Central Nervous System Tumors and Neuroblastoma and is currently completed. Children's Oncology Group leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Oncology Group
National Cancer Institute (NCI)

Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Albuquerque, United States , Amarillo, United States , Ann Arbor, United States , Asheville, United States , Atlanta, United States , Auckland, New Zealand , Augusta, United States , Austin, United States and 164 more locations